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Abstract
Background: Chronic neuropathic pain is a common symptom of multiple sclerosis (MS). MOG35–55-induced
experimental autoimmune encephalomyelitis (EAE) has been used as an animal model to investigate the
mechanisms of pain in MS. Previous studies have implicated sensitization of spinal nociceptive networks in the
pathogenesis of pain in EAE. However, the involvement of supraspinal sites of nociceptive integration, such as
the primary somatosensory cortex (S1), has not been defined. We therefore examined functional, structural, and
immunological alterations in S1 during the early stages of EAE, when pain behaviors first appear.
We also assessed the effects of the antidepressant phenelzine (PLZ) on S1 alterations and nociceptive (mechanical)
sensitivity in early EAE. PLZ has been shown to restore central nervous system (CNS) tissue concentrations of GABA and
the monoamines (5-HT, NA) in EAE. We hypothesized that PLZ treatment would also normalize nociceptive sensitivity
in EAE by restoring the balance of excitation and inhibition (E-I) in the CNS.
Methods: We used in vivo flavoprotein autofluorescence imaging (FAI) to assess neural ensemble responses in S1 to
vibrotactile stimulation of the limbs in early EAE. We also used immunohistochemistry (IHC), and Golgi-Cox staining, to
examine synaptic changes and neuroinflammation in S1. Mechanical sensitivity was assessed at the clinical onset of
EAE with Von Frey hairs.
Results: Mice with early EAE exhibited significantly intensified and expanded FAI responses in S1 compared to controls.
IHC revealed increased vesicular glutamate transporter (VGLUT1) expression and disrupted parvalbumin+ (PV+)
interneuron connectivity in S1 of EAE mice. Furthermore, peri-neuronal nets (PNNs) were significantly reduced
in S1. Morphological analysis of excitatory neurons in S1 revealed increased dendritic spine densities. Iba-1+
cortical microglia were significantly elevated early in the disease. Chronic PLZ treatment was found to normalize
mechanical thresholds in EAE. PLZ also normalized S1 FAI responses, neuronal morphologies, and cortical microglia
numbers and attenuated VGLUT1 reactivity—but did not significantly attenuate the loss of PNNs.
Conclusions: These findings implicate a pro-excitatory shift in the E-I balance of the somatosensory CNS, arising early
in the pathogenesis EAE and leading to large-scale functional and structural plasticity in S1. They also suggest a novel
antinociceptive effect of PLZ treatment.
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Background
In addition to progressive paralysis and the formation of
white matter plaques, multiple sclerosis (MS) is often asso-
ciated with prominent secondary symptoms [1]. Sensory
alterations, including pain and dysesthesia, are frequently
reported in the clinical MS population [2, 3]. A substantial
proportion of those affected (up to 40 %) suffer from pain
of central neuropathic origin (CNP) [4, 5]. An increasing
awareness of these issues has developed in parallel with an
increased focus on the importance of gray matter alter-
ations in the pathobiology of MS [6]. Furthermore, a
connection between maladaptive plasticity within pain-
associated gray matter regions of the brain—such as the
primary somatosensory cortex (S1)—and CNP has been
established in the literature [7–9].
Several recent studies and reviews have indicated that the
disease model, experimental autoimmune encephalomyeli-
tis (EAE), shares multiple pathobiological characteristics
with MS beyond the hallmark symptoms of demyelination,
paralysis, and frank neurodegeneration [10]. Wide-spread
gray matter synaptopathy, driven by diffuse and persistent
neuroinflammation throughout the central nervous system
(CNS) is emerging as a critical contributing factor in the
loss of function, sensory and cognitive abnormalities [11],
and potentially in pain—which is also now known to fea-
ture prominently EAE. These reports provide an experi-
mental foundation for investigations into the connections
between these phenomena in diseases like MS/EAE. Specif-
ically, earlier studies by Olechowski et al. [12–14] and
others [15–17] established the suitability of the female C57/
BL6 mouse model of EAE for the study of the underlying
mechanisms of CNP in MS. These studies revealed that
mice with EAE develop robust mechanical and thermal
allodynia prior to the onset of paralytic symptoms. They
also found evidence of hyperexcitability within the dorsal
horn of the spinal cord (SC-DH), a form of central
sensitization [12, 18]. While a few previous reports have
highlighted the existence of altered neuronal structure and
function in the neocortex of animals with EAE [19–21], no
study to date has directly examined changes in neuronal ac-
tivity and structure in higher sensory cortex in connection
with altered pain behaviors in the early stages of the
disease.
S1 is known to play a critical role in processing “sen-
sory-discriminative” aspects of both painful and non-
painful touch. Within S1, the body-centric locations of ex-
ternal stimuli are encoded as a spatially organized “soma-
totopic map” comprised by distinct regions of cortical
activation. The intensity (or perceived intensity) of an ex-
ternal stimulus is encoded as the magnitude of cortical ac-
tivation (the extent of neuronal spiking activity, within an
ensemble) in S1. Painful stimuli, which are generally per-
ceived as being more intense, are associated with a greater
magnitude of activation in S1 [22]. Allodynia, such as in
EAE/MS with CNP, involves non-noxious stimuli being
perceived as painful—and is thought to involve intense
activation (hyperexcitability) in S1 and connected
“pain-associated” brain regions [23–25]. Indeed, plasti-
city and enhanced activation in S1 has been shown to
enhance activation in other “pain regions,” such as the
anterior cingulate cortex, and to enhance chronic pain
states [7, 23].
In the current study, we quantified synaptic densities
and neuronal morphologies in S1 of female C57/BL6
mice with EAE using histological methods. This in-
volved immunostaining for vesicular glutamate trans-
porter (VGLUT1)+ presynaptic excitatory terminals and
parvalbumin+ (PV+) inhibitory networks and reflectance-
mode confocal microscopy of Golgi-Cox-stained cortical
neurons. We also quantified sensory-evoked functional
neuronal responses in S1 of EAE mice using in vivo flavo-
protein autofluorescence imaging (FAI). FAI has recently
been employed in several studies of cortical (S1) responses
to noxious and non-noxious peripheral stimuli in rodents
under acute urethane-induced anesthesia. This technique
measures increases in endogenous green fluorescence,
produced by oxidized flavoproteins within the mito-
chondrial respiratory chain, as a quantitative and non-
hemodynamic index of neuronal energy metabolism
and activity [26]. The FAI signal has been shown to ex-
hibit a roughly linear correspondence with local-field
potentials and intracellular calcium rises and with
stimulus amplitude, frequency, and duration [27].
These features make FAI an ideal technique for investi-
gating cortical nociceptive responses in EAE and for
the assessment of novel antinociceptive treatments.
The antidepressant phenelzine (PLZ) is an atypical
monoamine oxidase inhibitor (MAOI). We have previ-
ously demonstrated that EAE is associated with a reduc-
tion in CNS tissue concentrations of the monoamine
neurotransmitters (NTs) serotonin (5-HT), noradren-
aline (NA), and dopamine (DA), as well as gamma-
amino butyric acid (GABA) [28]. PLZ can restore CNS
tissue concentrations of all of these NTs when given
chronically to mice with EAE [29]. PLZ therefore com-
bines the features of both an anticonvulsant and an anti-
depressant—the net effect of which, we predicted, would
be a promotion of neuronal inhibition within the CNS.
As two recent reviews have speculated that a chronic
pro-excitatory/disinhibitory state may exist in the CNS
in MS/EAE [10, 11], and as both pain and neocortical
plasticity are thought to be regulated by a precise bal-
ance of CNS excitation and inhibition (E-I) [30, 31], we
hypothesized that a disrupted E-I balance might underlie
both conditions in EAE. We also hypothesized that re-
storing this balance, by bolstering CNS inhibition with
PLZ, would be an effective approach to treatment for
these symptoms of the disease.
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Methods
Mice and behavioral testing
A total of 116, 8–12-week-old, female C57/BL6 mice
(Charles River–Saint Constant, Quebec, Canada) were
used in these experiments. Mice were housed 5 per cage,
in standard cages, and fed ad libitum. All animal experi-
ments and procedures were conducted in accordance
with the Canadian Council on Animal Care’s Guidelines
and Policies and with protocols approved by the Univer-
sity of Alberta Health Sciences Animal Care and Use
Committee.
EAE induction
EAE was induced in mice by subcutaneous (S.C.) injec-
tion into the hindquarters of 50 μg of myelin oligo-
dendrocyte glycoprotein (MOG35–55), obtained from the
Peptide Synthesis Facility at the University of Calgary
(Calgary, Alberta, Canada), and emulsified in Complete
Freund’s Adjuvant (CFA, 1.5 mg/mL) containing add-
itional heat-killed Mycobacterium tuberculosis H37Ra
(Difco Laboratories/BD Biosciences—Franklin Lakes, NJ,
USA). Immunized mice also received two intraperitoneal
(IP) injections of pertussis toxin (Bordatella pertussis)
(PT, List Biological Labs—Campbell, CA, USA)—first,
on the day of the induction and again 48 h later. Control
mice received identical CFA with added M. tuberculosis
H37Ra (S.C./hindquarters), but without MOG35–55. CFA
mice also received PT injections on the same days.
Disease scoring
Mice were scored daily for clinical disease severity by an
observer blinded to the treatment groups, using a stand-
ard five-point scale (grades 0–4) defined as follows [32]:
grade 0—normal mouse, no loss of motor function; grade
1—flaccid tail, paralyzed in ≥50 % of the tail’s length, or
partial paralysis of the tail with visible weakness in one
or more of the limbs; grade 2—completely paralyzed tail,
some hindlimb weakness, preserved righting reflex; grade
3—severe hindlimb weakness, slowed righting reflex;
grade 4—complete paralysis of one or both of the hin-
dlimbs. “Clinical onset” or “disease onset” was defined as
the first day an animal scored a clinical grade of 1 or
higher. Except in the “pre-symptomatic” experiments
(and excluding CFA/naïve controls), only mice that de-
veloped clinical signs of EAE were included in the
analyses.
Drug treatments
For behavioral experiments, mice were divided into
groups that, starting at 7 days post-induction (dpi), re-
ceived daily IP injections of either vehicle (VEH, bac-
teriostatic water, 10 mL/kg body weight) or phenelzine
(PLZ, 15 mg/kg body weight, Sigma-Aldrich—Oakville,
ON, Canada). For EAE animals receiving PLZ, drug was
given on alternate days with injections of VEH given on
the “off” day. This design was intended to control for mul-
tiple IP injections, as previous experiments showed that
for longer experiments (a 21-dpi fixed endpoint was se-
lected for this behavioral/“established” histology cohort),
the effectiveness of GABA-transaminase (GABA-T) inhib-
ition is better maintained by this injection schedule [33].
For the “onset” FAI/histology (Golgi-Cox) experiment,
treatment was conducted in identical fashion; except ani-
mals in the (EAE- and CFA-) PLZ groups received the
drug daily, rather than having the drug alternated with in-
jections of VEH.
Pain testing/Von Frey hair assay
The Von Frey hair (VF/VFH) assay was used to assess
mechanical (tactile/punctate pressure) sensitivity and
allodynia [34]. Animals were placed in transparent plexi-
glass boxes over a screen that allowed access to the paws.
Prior to the start of testing, all mice underwent a period of
habituation to the boxes (5–10 min/day, for 3 days before
baseline testing began). Mice were also given 5–10 min of
habituation time in the testing boxes at the start of each
test day. After this period, the plantar surface of each hind-
paw was stimulated ×5 with a weighted Von Frey hair
monofilament. An observer blinded to the experimental/
treatment groups monitored and recorded behavioral re-
sponses to stimulation. “Noxious responding” (i.e., shaking,
licking, or guarding of the paw) was noted. Hindpaw
stimulation was repeated through a progressive series of
filament weights (0.04–2.0 g), until a stimulus produced a
“noxious response” ≥60 % of the time—the weight at which
this occurred was taken to be the withdrawal threshold for
that paw on that day. Left and right paw responses were av-
eraged within each animal to provide a combined threshold
for each test day, and these combined thresholds were used
for subsequent analysis. Prior to disease induction, all ani-
mals underwent VFH testing on three separate days to es-
tablish baseline mechanical thresholds. After induction,
mice were tested on days 3, 7, 9, and 12 post-induction and
at clinical onset. CFA animals from 7–12 dpi were used in
the “onset” analysis: n = 5 from each of days 7, 9, and 12
for the VEH group. PLZ-treated CFAs were taken at
12 dpi, following 7 daily drug injections.
Rotorod
To confirm that there was no confounding influence of
motor impairment in EAE mice at this stage of the disease,
the Rotorod assay (Harvard Apparatus, Holliston, MA,
USA) was also administered alongside the VFH assay. Any
animals with a clinical grade of ≥2, or that could not suc-
cessfully complete the Rotorod task, remaining on the
Rotorod for the full duration of 180 s in at least one of the
three attempts, and additionally failed to respond in the
VFH (obtained a 2.0 g threshold, the maximum), were
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excluded from the behavioral analysis (n = 3). After ex-
cluding these animals, none of the groups differed in
terms of their (mean) duration spent on the Rotorod
(group means, avg. of 3 attempts/95 % C.I. of mean: CFA
173.6 s/±6.1 s; EAE-VEH 126.7 s/±68.6 s; EAE-PLZ
157.8 s/±39.8 s—Kruskal-Wallis one-way analysis of vari-
ance (ANOVA) on ranks not significant, p = 0.242).
In vivo FAI of S1
FAI through a thinned-skull window has several methodo-
logical advantages over other functional imaging tech-
niques. It is minimally invasive to the animal and avoids
certain experimental pitfalls common to more invasive
methods, which frequently involve at minimum a craniot-
omy (electrophysiology, calcium imaging). By imaging
through a thin window, we minimized the risk of exposing
the brain to inadvertent physical trauma and/or periods of
hypoxia/tissue exposure and avoided inducing excess in-
flammation/infection at the site of the cranial window.
Furthermore, since the FAI signal is endogenous, no add-
itional (and potentially disruptive or toxic) extrinsic com-
pounds had to be applied to the brain [26, 35].
Animal preparation (thin window)
Mice at 7–9 dpi (“pre-symptomatic”) (n = 4 EAE mice, n =
5 CFA mice) or clinical onset (n = 8 VEH-treated CFA
mice at matched time points, n = 4 PLZ-treated CFA mice
at 14–17 dpi, n = 8 VEH-treated EAE mice, n = 10 PLZ-
treated EAE mice) were imaged acutely through a
thinned-skull window [36], before being euthanized for
histological analysis. Animals did not receive any treat-
ment injections on the day of the procedure. Prior to sur-
gery, mice were lightly anesthetized with urethane (1.25 g/
kg body weight IP, plus supplemental doses as required,
dissolved at 20 % w/v in 0.9 % saline). Urethane was
chosen as it provides stable and long-lasting anesthesia,
and does not uncouple mitochondrial respiration in neu-
rons (unlike volatile anesthetics [37]), making it suitable
for FAI [38]. Relative to other anesthetics (such as pento-
barbital or ketamine), urethane also does not strongly or
preferentially modulate CNS GABA or glutamate function,
and does not significantly interfere with evoked neuronal-
ensemble responses, provided the dosage is appropriate
and the achieved depth of anesthesia consistent [39, 40].
Anesthetized mice were placed in a modified stereotaxic
apparatus, with body temperature continuously monitored
and maintained at 37 °C by a rectal thermometer and heat-
ing pad. The hair of the scalp was grazed, and a local
anesthetic (bupivacaine, 0.1 mg S.C.) was administered to
the incision area. A rostrocaudal incision (approximately
1 cm in length) was made at the midline, and the overlying
skin was pulled back to expose the dorsal surface of the
skull. Any underlying connective tissue was cleared away
to reveal the underlying bone. Under a dissecting
microscope, bregma was located and used as a reference
to locate the region of interest (ROI) above the right pri-
mary somatosensory cortex (S1HL/FL, centered 2 mm lat-
eral from midline, 0.5 mm caudal to bregma) [41]. A
circle, 3 mm in diameter, was traced over the ROI to de-
marcate the boundaries of the window. Using a high-speed
dental drill, the skull was progressively thinned to the
point where the underlying vasculature was clearly visible
(approximately 30 % of the original thickness). During this
process, physiological saline was periodically dripped onto
the skull to aid with visualizing the region and to prevent
frictional heating. Particular attention was paid to ensuring
that excessive mechanical pressure, which can cause blood
to pool beneath the window, was not applied during the
thinning process. This is necessary because blood absorbs
light and scatters both the excitation and emission wave-
lengths for FA imaging. Once a smooth cranial surface
was obtained at the appropriate depth, the animal was
transferred to the imaging setup.
FA imaging
After preparation, animals in the stereotaxic frame and
held at normothermia were positioned into the imaging
setup. The imaging setup consists of a binocular epifluor-
escence microscope (TCS SP5 MP—Leica Microsystems,
Wetzlar, Germany) equipped with ×2.5 objective lens.
Under blue excitation light (450–490 nm, I3 filter-
cube—Leica) generated by a 120-W metal-halide lamp
(Leica EL6000), images of the brain’s endogenous green
(>515 nm) fluorescence were captured from a software-
controlled frame-grabber (EPIX PIXCI™ EL1—EPIX Inc.,
Buffalo Grove, IL, USA) connected to a 12-bit CCD cam-
era (DALSA Pantera™ DS-21-01 M60—Teledyne Dalsa,
Waterloo, ON, Canada). This setup employs a dichroic
mirror (510 nm) to accommodate separate light paths for
excitation and emission wavelengths, preventing contam-
ination and dilution of the relatively weak fluorescence sig-
nal by the much larger blue-green reflectance signal [27].
In order to improve detection of the weak fluorescence
signal and enhance the signal-to-noise ratio, the camera
was also set to 4 × 4 spatial binning. The animal’s left fore-
and hindlimb were positioned into computer-triggered
vibromechanical stimulators incorporating piezoceramic
actuators (Piezo Systems, Woburn, MA, USA) [42]. All ex-
ternal light sources were removed by dimming the light in
the room and covering the imaging setup with an opaque
black curtain. Extraneous vibrational sources were con-
trolled by the use of an air table. Imaging trials involved
the continuous capture of frames for 7.5 s at 4 hz (250 ms
exposure, 31 frames) for “pre-symptomatic” imaging, or
for 6 s at 5 hz (200 ms exposure, 31 frames) for “onset”
imaging, with the stimulus (1 mm deflection, 100 hz, 1 s
stimulus duration) being delivered after the first second.
These relatively long exposure times were necessary to
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reliably detect the weak fluorescence signal; however, the
temporal resolution we obtained was adequate, as the time
course of the in vivo sensory-evoked FA signal in mouse
S1 is relatively slow (in the order of seconds). In order to
obtain a consistent and accurately quantifiable FA re-
sponse, each imaging session was comprised of 40 re-
peated trials per limb (alternating fore- and hind-), with a
20-s interstimulus interval to allow activity to return to
baseline. All images were stored as uncompressed 256 ×
256 pixel grayscale TIFF stacks.
FA image processing and data analysis
Data analysis was performed using NIH ImageJ 1.43/FIJI
software equipped with the Intrinsic Signal and VSD
Processor plugin (v1.0.8, written by Albrecht Sigler) ob-
tained from the website of Dr. Timothy Murphy [43].
Briefly, in order to obtain a representative response and
improve signal-to-noise ratio, all trials from a given limb
and session were averaged to provide a mean time series.
Prior to averaging, all trials were manually inspected for
any obvious motion, light, or equipment artifacts that
might obscure the signal (due to their much larger rela-
tive magnitudes). The plugin’s automated data quality al-
gorithm was also used to detect trials that deviated
strongly from the mean response (i.e., ≥10 % frame-by-
frame deviation in the average gray value from the mean
z-stack). Any trials contaminated by artifacts, or with a
highly deviating response profile, were excluded from
the analysis. A Gaussian filter (r = 1.0 pixel) was applied
to all images in the x,y directions to reduce high fre-
quency noise. In order to control for global differences
in basal cortical activity, tissue autofluorescence, and
ambient light levels, all responses were normalized to a
percent change in fluorescence vs. baseline (%ΔF/F). A
“baseline” image was calculated from the mean time
series as the (pixel-by-pixel gray value) average of the
frames immediately preceding the onset of stimulation. A
“response” frame was defined for each session as the
frames that, following the onset of stimulation, comprised
the primary FA response (i.e., from the initial upward in-
flection point or signal onset—to the zero intercept, or
signal offset), as determined from the intensity-vs.-time
plot of the mean time series. The baseline image was sub-
tracted from all images in the series to create a “difference
series.” All images in the response frame (of the difference
series) were then divided by the baseline image (and
multiplied by 100) to yield a time series of images in which
the intensity of each pixel indicated the % change in inten-
sity vs. baseline (%ΔF/F) [44].
This (%ΔF/F) time series was then quantified along the
following parameters: time of signal onset, time to peak
response, duration of the attack phase, duration of the
decay phase, and total response duration (only decay-
duration data is shown—although total response duration
differed between treatment groups, this was accounted for
by changes in decay duration). In the spatial domain, the
areal extent of the “cortical map” (i.e., response area) was
quantified. This “cortical map” was defined as the area
where the %ΔF/F was >50 % of its maximal value in a
(mean) z-projected image of the response frame. An ROI
was drawn around this “map” area, and the (ROI-wide)
mean intensity (%ΔF/F) was plotted vs. time, in order
to determine the intensity at peak response. For the
“surround-inhibitory” FA signal analysis, an ROI was
drawn manually around the darkened regions adjacent
to the “cortical map,” and the peak (negative) %ΔF/F
intensity value was thereby attained.
Histology
Histological analysis was performed on brain tissues ex-
tracted from CFA controls and EAE (untreated, VEH-
treated, PLZ-treated) mice at the various experimental
endpoints: “pre-symptomatic” (7–9 dpi/post-FAI), “clin-
ical onset” (the day a mouse first presented as clinical
grade 1 or higher, post-FAI; CFA endpoints matched)
and at the “established disease” endpoint of 21 dpi. In
order to improve certain group sizes and obtain greater
statistical power, “additional onset” brains (referred to in
the subsequent text) were obtained from a separate co-
hort of CFA/EAE mice that received no drug treatments,
but did receive similar behavioral habituation and base-
line assessments, were fixed at clinical onset (7–9 dpi for
CFA animals) for tissues. Statistical comparisons con-
firmed that these mice did not differ significantly from
the initial cohorts on the applicable measures.
Tissue extraction and fixation
For “pre-symptomatic” and “clinical-onset” cohorts, depth
of anesthesia was assessed immediately after FAI. Any ani-
mals that required additional anesthesia were put into a
chamber supplied with isoflurane/O2 mixture at 5 % w/v,
3 L/min at 14.7 psi for approximately 1 min. For behav-
ioral/histology cohorts (“additional onset” and “established
disease” immunohistochemistry (IHC)), mice were anes-
thetized with sodium pentobarbital (1.7 g/kg IP). Fully
anesthetized mice underwent exsanguination and fixation
by transcardiac perfusion with 4 % w/v paraformaldehyde
(PFA) in 0.1 M phosphate buffer (PB). For Golgi-Cox
staining, extracted tissues (whole brains from the “clinical-
onset” FAI experiment) were briefly immersed in ddH2O
and then placed immediately into Golgi-Cox solution (see
below). For IHC, extracted tissues were post-fixed in 4 %
w/v PFA/0.1 M PB for at least 24 h and then immersed in
30 % w/v sucrose solution in 0.1 M PB overnight, before
being snap frozen with isopentane on solid carbon diox-
ide. Frozen tissues were stored at −80 °C prior to section-
ing on a cryostat (50 μm) as free-floating sections (see
below, “established disease” cohort only) or immediately
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mounted onto slides (“pre-symptomatic” and “onset”
histology).
Free-floating sectioning
For “established disease” histology, free-floating sections
were stored in phosphate-buffered saline solution (PBS) at
4 °C until they could be stained. After staining with a
standard IHC protocol (see below), sections were mounted
onto slides and coverslipped with Vectashield® Mounting
Medium with DAPI (Vector Laboratories Inc., Burlingame,
CA, USA).
Golgi-Cox staining
We performed Rapid Golgi-Cox staining, combined with
reflectance-mode laser-scanning confocal microscopy, on
tissue sections incorporating S1 from CFA, VEH-treated
EAE, and PLZ-treated EAE mice at clinical onset. Immedi-
ately after FAI, extracted brains were immersed in Rapid
Golgi-Cox solution (“Solutions A/B,” FD Rapid GolgiStain
Kit™, FD Neurotechnologies—Columbia, MD, USA) for
14 days (changing the solution once after 24 h) at RT/low
ambient light, before being transferred into cutting solution
(“Solution C”). Brains were sectioned on a vibratome (Leica
VT1200S) at 200 μm to ensure that whole (untransected)
neuronal arbors could be accommodated [45] and then
mounted on gelatin-coated slides. Slides were further devel-
oped and processed according to the manufacturer’s in-
structions, before being coverslipped with Permount™
Mounting Medium (Fisher Scientific Co., Waltham, MA,
USA).
Spiny (excitatory/glutamatergic) neurons in cortical layers
2/3 and of S1—mainly pyramidal cells in layers 2/3, or stel-
late/star-pyramid (principal) cells in layer 4 [46, 47]—were
located by reference to a stereotaxic atlas [41] and identified
by their cytoarchitectonic/morphological characteristics.
This step was performed under bright-field illumination on
a Leica TCS SP-5 MP microscope by an unbiased observer.
Three-dimensional z-stacks of these neurons were then ac-
quired from the same microscope in confocal reflectance
mode (488 nm argon laser, 30/70 R/T filter), equipped with
a ×20 objective water-immersion lens (1.0 NA). Only neu-
rons that were completely stained and unbroken were se-
lected for acquisition to ensure that accurate quantifications
could be obtained. Whenever staining permitted, at least
two neurons from each layer were chosen from each animal
for analysis. Z-stacks of the neurons’ entire dendritic arbors
were acquired (2048 × 2048 pixels, pixel-size 240 × 240 nm,
z-length: 0.54 μm, ×2 line/frame averaging) using Leica’s
LAS-AF™ software suite. The observer then manually se-
lected representative dendritic segments and manually
counted the total number of spines (protruding in all three
planes) along their lengths using FIJI/ImageJ [48]. Only pro-
trusions with a distinctly formed neck and head were con-
sidered to be dendritic spines (“stubs” and filopodia were
not included in the counts). For each neuron, a minimum
of 3 and a maximum of 9 dendritic segments were analyzed,
with an effort made to sample equally from proximal and
distal branches and from the apical and basilar tufts (when
staining permitted). This resulted in a total of n = 42 neur-
ites from 8 layer 2/3 neurons and n = 47 neurites from 10
layer 4 neurons (5 mice) for the CFA group. For the EAE-
VEH group, n = 66 neurites from 14 layer 2/3 neurons and
n = 76 neurites from 14 layer 4 neurons (8 mice) were ob-
tained, and for the EAE-PLZ group, n = 79 neurites from 18
layer 2/3 (9 mice) and n = 83 neurites from 20 layer 4 neu-
rons (10 mice). Dendritic segment lengths were determined
using the Simple Neurite Tracer plugin for FIJI/ImageJ [49],
and the spine density of each segment was calculated by
dividing the total number of spines by the length of the cor-
responding segment.
Immunohistochemistry: antibodies/reagents
Tissues were stained using a standard IHC protocol with
the following commercially available antibodies: rat anti-
cluster of differentiation (CD)3 (1:200 concentration, AbD
Serotec®—BioRad Laboratories Canada Ltd., Mississauga,
ON, Canada), rat anti-CD45 (1:200, AbD Serotec®), rabbit
anti-ionized calcium-binding adapter (Iba)-1 (1:500, Wako
Chemicals USA Inc., Richmond, VA, USA), mouse anti-PV
(1:2000, Cedar Lane, Burlington, ON, Canada), rabbit anti-
VGLUT1 (1:1000, Cell Signaling Technology, Danvers,
MA, USA), and Wisteria floribunda lectin (WFA, 1:1000,
Vector Laboratories). Primary antibodies were visualized
with the following fluorescent secondary antibodies: goat
anti-rabbit Alexa Fluor®488 (1:200, Invitrogen™—Life Tech-
nologies Inc., Burlington, ON, Canada), donkey anti-rat
488 Alexa Fluor®488 (1:200), Alexa Fluor® 647 streptavidin
(1:200), and goat anti-rabbit Alexa Fluor®594 (1:200). Se-
lected PV-stained slides that were used in the “perisomatic”
analysis were counterstained with NeuroTrace® 530/615
Red Fluorescent Nissl Stain (“fluoronissl”—ThermoFisher
Scientific, Waltham, MA, USA) according to the manufac-
turer’s instructions. All slides were coverslipped using Vec-
tashield® with DAPI.
IHC: image acquisition
Low-power images were captured on a Leica DMI
6000B microscope equipped with a ×5 objective lens
(×50 total magnification). Higher magnification images
required for the VGLUT1 analysis were acquired on a
Zeiss Observer Z.1 inverted microscope equipped with a
×40 objective lens (×400 total magnification). For the
“perisomatic” PV analysis, three-dimensional high-
resolution (2048 × 2048 pixels, 0.301 μm× 0.301 μm pixel
size, 0.615 μm optical slice thickness, ~30 slices) con-
focal fluorescence z-stack images were acquired (focused
on L2/3 in S1HL, 1 image per section, 2 sections per
slide, 2 slides per animal) with a Leica TCS SP-5 MP
Potter et al. Journal of Neuroinflammation  (2016) 13:142 Page 6 of 20
microscope equipped with a ×20 objective water-
immersion lens (1.0 NA). For VGLUT1 analysis, 4 im-
ages from (S1HL) layer 2/3, and 4 images from layer 4/5
were taken from at least 2 sections per slide and 1 or 2
slides per animal. All other measurements (Iba-1, WFA,
and PV) were taken as the average of 3 sections per slide
and 1 slide per animal (see Table 1 for histology sample
sizes). Image acquisition parameters remained consistent
within each analysis. All quantitative IHC image analyses
were performed on either the original unmodified images
or on images processed in a consistently applied manner
as described elsewhere in the methods. Representative
photomicrographs used in figures were additionally ad-
justed for brightness, contrast, color balance, and histo-
gram scaling in order to improve the overall visibility of
the images. These adjustments were performed only on
whole images and were applied in a consistent a manner
such that the figures accurately reflect the entire contents
and relative intensities of the original images.
IHC: analysis
CD3/CD45 staining was not quantified, as no infiltrating
cells were present in any of the slides. For all other stains,
images were quantified by an unbiased observer blind to
treatment groups. Apart from the “perisomatic” PV analysis
(see below), images were quantified with NIH ImageJ/FIJI.
S1 hindlimb region (S1HL) and individual cortical layers
therein were identified visually by inspecting cytoarchitech-
tonic features and by making reference to stereotaxic at-
lases [41, 50]. An ROI over S1HL was manually drawn, and
the total area of this ROI measured to ensure it remained
consistent across all images and animals (the standard de-
viation for ROI area remained below 5 % at all times).
Within this ROI, quantifications of parvalbumin-positive
(PV+) and Iba-1+ cells were performed using the ITCN-
automated cell-counting plugin for ImageJ (by Thomas
Kuo et al. [51]). PV+ cell quantifications were performed
for 7–9 dpi CFA control mice, “pre-symptomatic” EAE,
and “additional onset” EAE groups, as well as for all “estab-
lished” (21 dpi) groups (CFA, EAE-VEH, EAE-PLZ). Quan-
tification of WFA staining was performed by manually
counting peri-neuronal nets (PNNs) in the ROI. For
VGLUT1 analysis, a custom Fiji macro was used to create
an ROI of consistent dimensions/area in each image and
subsequently return the integrated density within that ROI.
IHC: analysis (“perisomatic” PV)
Perisomatic PV staining was quantified using a custom
Matlab application (created by Liam Potter, using ele-
ments of code and guidance from Dr. Majid Mohajerani,
University of Lethbridge, Canada). This program was de-
signed to operate on confocal images that had been
“pre-processed” with a custom FIJI script, the purpose of
which was to produce images of manageable file size, re-
duce image “noise,” and achieve better separation of the
relevant foreground pixels from image background.
Briefly, a 1-pixel-radius median filter was applied to each
z-stack. Filtered stacks were group z-projected (by max
intensity; 5 slices to 1 slice), followed by the manual se-
lection of 2 or 3 consecutive “in-plane” (properly gained/
artifact/distortion-free) z-projected images from each
stack. These images were concatenated to form a new
“compressed” z-stack. Compressed z-stacks were binar-
ized using an automatic local thresholding function
(Bernsen algorithm, 15-pixel radius). Following this pre-
processing, a final “control” image was added at the end
of the binarized stack by performing a watershed trans-
form on a single “guide” image chosen from the stack.
This “guide” image was selected to be one that contained
many basket-cell outlines (i.e., “perisomatic” staining
surrounding a putative pyramidal cell shadow). These
shadows were later confirmed as pyramidal neurons by
examining the fluoronissl counterstain. The watershed
transform applied to the “guide” image served to close-
off the spatial boundaries of these shadows so a region-
growing algorithm could be applied.
Final processed/binarized stacks were loaded into the
Matlab viewer, and an unbiased operator was then able to
“click” inside these cell “shadows,” triggering the region-
growing algorithm in the “control” image, followed by
morphological dilation, to define the “perisomatic” ROI
for that neuron. This ROI was then used as a Boolean
mask to obtain the total number of “above-threshold”
(white) pixels captured therein from each image in the
stack (excluding the “control image”). After adding up
the areas from each image in the stack (yielding a
“pseudo-volume”), the resulting sum was normalized to
the cross-sectional area of the “shadow neuron” (the
initial undilated area of the ROI) and divided by the number
of images in the (compressed) z-stack (excluding the “con-
trol image”). The final quantity obtained for each neuron
was therefore a stack- (or “volume-”) averaged ratio of total













CFA 4/4 8/8/6 8/8 8/5 11/11/6 13/13/6
EAE (VEH) 4/4 4/4/7 4/4 4/5 4/8/7 4/8/7
EAE (PLZ) 4/4 –/–/4 –/4 –/4 –/–/4 –/–/4
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stained area (adjacent the neuron) to the neuronal cross-
sectional area. Approximately 25 “shadows” were analyzed
per confocal stack (i.e., approx. 100 neurons per animal).
The program operator was able to avoid inadvertently cap-
turing any PV+ somas, confounding tissue artifacts, non-
neuronal hypo/hyperintensities, and poorly binarized areas
in the images by constant visual comparison with the un-
processed original confocal stacks during the analysis.
Statistics
Statistical analyses were carried out using (the two-tailed)
Student’s t test or by one-way ANOVA with additional
post hoc tests. The Holm-Sidak method was generally
used for all pairwise post hoc comparisons (Student-
Newmnn-Keuls (SNK) method was used for layer 4 20
branches Golgi-Cox analysis), whereas Dunnett’s method
was used when only post hoc comparisons against the
control group were required. For non-parametric data, or
cases where assumptions of normality/homogeneity of
variances were not met, the Mann-Whitney rank-sum test
or the Kruskall-Wallis one-way ANOVA (with post hoc
comparisons against the control group by Dunn’s method)
was used. Significance (α) was set at p < 0.05.
Results
Mice with EAE exhibit enhanced neuronal responses to
tactile stimulation within S1 pre-symptomatically
To examine whether EAE involves changes in the func-
tional (neuronal) activation of S1, we used FAI to measure
responses in the forelimb (FL) and hindlimb (HL) cortex
regions (S1FL/HL), evoked by a “non-noxious” vibrotactile
(mechanical) stimulus. We first imaged naïve and CFA-
only controls, along with EAE animals at a “pre-symptom-
atic” time point (7–9 dpi)—prior to any clinical signs of
the disease, but when mechanical allodynia has been ob-
served [14]. Vibrotactile-evoked FAI responses in S1HL
were significantly more intense in the EAE group than in
CFA-only controls or “naïve” animals (one-way ANOVA,
p = 0.012; all pairwise post hoc comparisons by Holm-
Sidak method) (Fig. 1a, b). The area of cortical activation
elicited by this stimulus was also significantly larger in the
EAE group compared to naïve animals or mice treated
with CFA only (one-way ANOVA, p = 0.009; all pairwise
post hoc comparisons by Holm-Sidak method) (Fig. 1c—an
additional movie depicts representative HL responses (see
Additional file 1: Video 1)).
When the HL-evoked FAI signal was analyzed in
the temporal domain, we found that the overall signal
duration—the time between stimulus onset and signal
offset—was prolonged in the EAE group when com-
pared to CFA-only or naïve animals. Specifically, the dur-
ation of the decay phase, or the time between signal-peak
and signal-offset, was significantly prolonged and accounted
for most of the overall increase in signal duration (one-way
ANOVA, p = 0.013; all pairwise post hoc comparisons by
Holm-Sidak method) (Fig. 1d). As CFA-only mice and naïve
mice did not differ in terms of evoked functional activation
of S1, and have also not been observed to differ in any of
the other relevant parameters (such as mechanical sensitiv-
ity), CFA-only mice were used as the control group in sub-
sequent analyses.
Early EAE is associated with changes in the density of
inhibitory and excitatory synaptic markers within S1
We next examined the possibility of a specific intracorti-
cal synaptic basis for the functional plasticity that we ob-
served with FAI in S1 in EAE mice. To this end, we
employed IHC on brain tissues collected post-FAI from
CFA-only and pre-symptomatic EAE mice and examined
the density of excitatory and inhibitory synaptic contacts
in S1HL.
We found no significant difference in the number
of parvalbumin-positive (PV+) inhibitory interneuron
cell bodies in S1 from EAE or CFA control mice (see
Additional file 2: Figure S1). However, we did observe a
significant reduction in perisomatic PV-immunoreactivity
around putative pyramidal neurons residing in cortical
layers 2/3 of S1 at the earliest time point (two-tailed t test
“pre” vs. CFA, p = 0.042) (Fig. 2a–c). Hypo-intense regions
or “shadows” in the dense PV staining, targeted in this
analysis, were visually confirmed to correspond with neur-
onal (mostly pyramidal) cell-bodies using fluoronissl
counterstaining (Fig. 2(a’)).
The presynaptic marker of excitatory synapses, VGLUT1,
is expressed at both thalamocortical and corticocortical glu-
tamatergic terminals throughout S1. In contrast to PV, we
found a significant increase in VGLUT1 density in layers 2/
3 and 4/5 of S1 in pre-symptomatic EAE animals, com-
pared to CFA controls (two-tailed t tests, L2/3: p = 0.041,
L4/5: p = 0.047) (Fig. 2d–i).
Chronic treatment with the antidepressant PLZ
normalizes vibrotactile-evoked FAI responses in S1 of
mice with EAE at clinical onset
Our next experiment characterized the effects of PLZ
treatment on vibrotactile-evoked FAI responses in S1 of
CFA/EAE mice at the clinical onset of the disease, the
time point when behaviorally measured allodynia is most
prominent in EAE mice [14]. CFA-only controls and
mice with EAE were treated with either vehicle (VEH)
or PLZ, beginning at 7 dpi. S1 responses to vibrotactile
stimulation of the limbs were imaged on the day when a
mouse first presented with clinical signs of the disease
(clinical onset/grade 1, flaccid paralyzed tail). As previ-
ously reported by Benson et al. [29, 33], PLZ treatment
in EAE delays clinical onset by several days on average
(see Additional file 3: Figure S2). Following onset, clin-
ical severity progresses in PLZ-treated EAE mice along
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an equivalent trajectory to that of VEH-treated EAE
mice. As observed in pre-symptomatic animals, VEH-
treated EAE mice exhibited significantly intensified HL-
evoked S1 FAI responses at clinical onset, compared to
control mice treated with CFA alone. Chronic PLZ treat-
ment in EAE animals normalized the intensity of HL-
evoked responses to levels similar to (VEH-treated) CFA
controls. PLZ-treated CFA animals did not significantly
differ from VEH-treated CFA or PLZ-treated EAE ani-
mals (one-way ANOVA, p < 0.001; all post hoc compari-
sons by Holm-Sidak method) (Fig. 3a, b).
Similar to what we observed at the pre-symptomatic
stage, the area of the HL-evoked S1 FAI response remained
significantly expanded at clinical onset in EAE mice treated
with vehicle. This functional “map” expansion in S1 of EAE
animals was normalized by PLZ treatment. PLZ treatment
did not significantly affect HL-evoked response area in CFA
animals (one-way ANOVA, p = 0.003; all pairwise post hoc
comparisons by Holm-Sidak method) (Fig. 3c). EAE ani-
mals at clinical onset also exhibited increased HL-evoked
FAI signal duration, which was mainly the result of a sig-
nificantly prolonged decay phase. Treatment with PLZ nor-
malized HL-evoked response/decay durations in EAE
animals at clinical onset but did not alter response dura-
tions in CFA animals (one-way ANOVA, p = 0.012, all pair-
wise post hoc comparisons by Holm-Sidak method)
(Fig. 3d—an additional movie depicts representative HL re-
sponses (see Additional file 4: Video 2). VEH-treated EAE
mice also displayed significantly more intense FAI re-
sponses in S1FL to forelimb stimulation at clinical onset.
PLZ treatment in mice with EAE normalized the intensity

























































































































































































Fig. 1 In vivo FA imaging of vibrotactile-evoked responses in S1 at the pre-symptomatic stage of EAE. a Balanced-contrast pseudocolored (%ΔF/
F) montages of representative hindlimb and forelimb responses in S1 of naïve, CFA, and pre-symptomatic EAE (7–9 dpi) animals. b Group mean
(±S.E.) signal intensities at peak FA response, calculated from the “cortical map” area as a percent change in fluorescence vs. baseline (%ΔF/F).
Pre-symptomatic EAE animals (n = 4) exhibited significantly intensified responses to vibrotactile stimulation of the hindlimb, but not the forelimb,
compared to naïve (n= 3) and CFA controls (n= 5). Naïve and CFA responses did not significantly differ from each other (one-way ANOVA, p= 0.012; all
pairwise post hoc comparisons by Holm-Sidak method). c Group mean (±S.E.) areas of the FAI response, calculated from (gray-value averaged)
z-projections of the response phase, and defined as the region exhibiting a ≥50 %-of-maximal increase in fluorescence vs. baseline (%ΔF/F).
Pre-symptomatic EAE animals (n = 4) exhibited significantly expanded hindlimb, but not forelimb, responses compared to naïve (n = 3) and
CFA-controls (n = 5). Naïve and CFA responses did not significantly differ from each other (one-way ANOVA, p = 0.009; all pairwise post hoc
comparisons by Holm-Sidak method). d Grand-average FA signal traces (thick traces; ±S.E. thin traces) of hindlimb responses in naïve (green
trace, n = 3), CFA (red trace, n = 5), and pre-symptomatic EAE (blue trace, n = 4) animals. Gray vertical bar shows time of stimulus onset. Overlying
bars indicate signal decay phase (time from peak signal intensity to x-axis intercept). At the right, group mean (±S.E.) decay phase durations as
bar plot. Pre-symptomatic EAE animals exhibited significantly prolonged FAI decay phase durations vs. naïve and CFA animals. Naïve and CFA
responses did not differ significantly from each other (one-way ANOVA, p = 0.013; all pairwise post hoc comparisons by Holm-Sidak method)
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CFA animals did not significantly differ from VEH-
treated CFA mice or PLZ-treated EAE animals for FL
parameters (Kruskal-Wallis one-way ANOVA on ranks,
p < 0.001 post hoc comparisons vs. CFA by Dunn’s
method) (see Additional file 5: Figure S3).
To determine whether measureable changes in func-
tional inhibition might contribute to the altered patterns
of activation observed in S1 of EAE animals [52–54], we
also quantified the magnitude of the early/adjacent
“surround-inhibitory/off-map” FAI signal. This signal
component indicates reduced neuronal spiking and oxi-
dative metabolism and has been shown to be GABA-A
receptor-mediated [55–57]. There was no significant dif-
ference in the magnitude of this negative signal compo-
nent between CFA control mice treated with either VEH
or PLZ, nor did we find any differences between VEH-
treated CFA controls and VEH-treated EAE mice (post



























































































Fig. 2 Perisomatic PV+ and VGLUT1+ reactivity in S1 at the pre-symptomatic stage of EAE. a, b Representative confocal z-projections of PV+ somas and
terminals (green) in layers 2/3 of S1, in control (7–9 dpi CFA) and pre-symptomatic (7–9 dpi PRE) EAE animals. White arrowheads indicate PV+
somas; magenta arrowheads indicate putative pyramidal-neuron “shadows” targeted for quantification. A’ (inset) High-magnification confocal
photomicrograph depicting fluoronissl (NeuroTrace™) counter-staining (red) in S1 of an EAE animal, confirming the neuronal identity of “shadows” targeted
for perisomatic PV analysis. White arrowheads indicate PV+ somas; magenta arrowheads indicate nissl+ (putative pyramidal) neurons. c Group mean (±S.E.)
normalized density values corresponding to perisomatic PV+ staining surrounding layer 2/3 neurons in S1. This quantity represents a volume-
above-threshold calculation which was normalized for target-cell cross-sectional and z-stack volume thickness. Mice with pre-symptomatic
EAE (n = 4) exhibited significantly reduced perisomatic PV+ staining in S1, compared to CFA-controls (n= 8) (*t test vs. CFA, p = 0.042). d, e Representative
coronal-plane fluorescence photomicrographs of VGLUT1+ staining (pre-synaptic excitatory terminals, red) in layers 2/3 of S1 in CFA (d) and
pre-symptomatic EAE (e) animals (7–9 dpi). DAPI (cell-nuclei) counter-stain is shown in blue. f Group mean (±S.E.) integrated density values for
VGLUT1+ staining in layers 2/3 of S1. Mice with pre-symptomatic EAE (n = 5) exhibited significantly denser VGLUT1+ staining in layers 2/3 of
S1, compared to CFA-controls (n = 5) (*t test vs. CFA, p = 0.041). g, h Representative coronal-plane fluorescence photomicrographs of VGLUT1+
(red) staining in layers 4/5 of S1 in CFA (g) and pre-symptomatic EAE (h) animals (7–9 dpi). DAPI (cell-nuclei) counter-stain is shown in blue. i Group
mean (±S.E.) integrated density values for VGLUT1+ staining in layers 4/5 of S1. Mice with pre-symptomatic EAE (n = 5) exhibited significantly denser
VGLUT1+ staining in layers 4/5 of S1, compared to CFA-controls (n = 5) (*t test vs. CFA, p = 0.047)
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found that the magnitude of this negative signal was
significantly greater in PLZ-treated EAE mice com-
pared to EAE mice treated with VEH (one-way
ANOVA, p = 0.007, all pairwise post hoc comparisons
by Holm-Sidak method) (Fig. 3a, e).
PLZ treatment normalizes nociceptive sensitivity in mice
with EAE
In order to confirm an association between S1 plasticity
and nociception in the EAE model, we characterized the
effects of PLZ treatment on withdrawal thresholds in re-
sponse to Von Frey hair (punctate mechanical) stimula-
tion. For this analysis, a separate cohort of CFA-only
and EAE mice were treated with either VEH or PLZ
from 7 dpi and assessed with VF hairs on the day of clin-
ical onset (CFA mice were assessed at matched time
points as described in methods). As we have demon-
strated previously [14], mice with EAE exhibit signifi-
cantly decreased mechanical withdrawal thresholds at
























































































































































































































Fig. 3 Chronic PLZ normalizes FAI responses in S1, and mechanical nociceptive thresholds, in EAE at clinical onset. a Balanced-contrast pseudocolored
montages of representative S1 hindlimb responses from VEH/PLZ-treated CFA/EAE animals at clinical onset. b Group mean (±S.E.) hindlimb FA response
intensities at peak (as %ΔF/F). EAE-VEH animals (n= 7) showed significantly intensified responses to hindlimb stimulation, compared to CFA-VEH controls
(n= 8), CFA-PLZ (n= 4), and EAE-PLZ (n= 9). CFA-VEH, CFA-PLZ, and EAE-PLZ groups did not significantly differ (one-way ANOVA, p≤ 0.001, all pairwise
post hoc comparisons by Holm-Sidak method). c Group mean (±S.E.) hindlimb FA response areas. EAE-VEH animals (n= 7) exhibited significant expansion
of hindlimb responses compared to CFA-VEH controls (n= 8), CFA-PLZ (n= 4), and EAE-PLZ animals (n= 9). CFA-VEH, CFA-PLZ, and EAE-PLZ groups did
not significantly differ (one-way ANOVA; p= 0.003, all pairwise post hoc comparisons by Holm-Sidak method). d Grand-average FA signal traces (thick
traces; ±S.E. thin traces) of hindlimb responses in CFA-VEH (n= 8), CFA-PLZ (n= 4), EAE-VEH (n= 7), and EAE-PLZ (n= 9). At the right, group mean (±S.E.)
decay durations. EAE-VEH animals at clinical onset exhibited significantly prolonged decay durations vs. CFA-VEH, CFA-PLZ, and EAE-PLZ animals.
CFA-VEH, CFA-PLZ, and EAE-PLZ groups did not significantly differ (one-way ANOVA; p = 0.012, all pairwise post hoc comparisons by Holm-Sidak
method). e Group mean (±S.E.) intensities from the (hindlimb) surround-region (as %ΔF/F) during the early inhibitory phase (red arrowheads in a). Inhibitory
responses in EAE-PLZ mice (n= 9) were significantly more intense than those in EAE-VEH (n= 7). CFA-VEH (n= 8), CFA-PLZ (n= 4), and EAE-VEH groups
did not significantly differ (one-way ANOVA, p= 0.007, all pairwise post hoc comparisons by Holm-Sidak method). f Group mean (±S.E.) response
thresholds to punctate mechanical stimulation of the hindpaws (Von Frey hairs) for CFA-VEH (7–12 dpi n = 15), CFA-PLZ (12 dpi n = 5),
EAE-VEH (n = 14), and EAE-PLZ (n = 17) mice at clinical onset. EAE-VEH mice exhibited significantly reduced mechanical thresholds compared to
CFA-VEH controls. Chronic treatment with PLZ from 7 dpi normalized mechanical thresholds in EAE at onset but did not affect thresholds in CFA mice
(Kruskal-Wallis ANOVA on ranks, p = 0.005; post hoc comparisons vs. CFA-VEH by Dunn’s method)
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normalized in EAE mice treated with PLZ and were not
significantly different from CFA controls. PLZ-treated
CFA mice did not differ significantly from VEH-treated
CFA or from PLZ-treated EAE animals (Kruskal-Wallis
one-way ANOVA on ranks, p = 0.005; all post hoc compar-
isons vs. CFA by Dunn’s method) (Fig. 3f). As no differ-
ences were observed between the PLZ- and VEH-treated
CFA groups in either evoked functional responses in S1 or
behaviorally assessed nociceptive sensitivity, the PLZ-
treated CFA group was not included in subsequent
analyses.
EAE is associated with morphological changes to
excitatory neurons of cortical layers 2/3 and 4 of S1,
which are prevented or reversed by PLZ treatment
Altered functional responses in the neocortex are often
a consequence of structural plasticity and modified con-
nectivity amongst excitatory pyramidal/principal neu-
rons [53]. Moreover, neuropathic pain states are
associated with the rapid remodeling of dendritic spines,
where the excitatory post-synaptic density is localized
[58], in excitatory neurons of S1. We therefore investi-
gated whether we could detect alterations in the density
of dendritic spines along the processes of spiny excita-
tory (principal and pyramidal) neurons in cortical layer 4
and layers 2/3 of S1. Layer 2/3 and layer 4 spiny (excita-
tory) neurons were found to exhibit greater overall spine
densities along the examined dendrites from the EAE-
VEH group (Kruskal-Wallis one-way ANOVA on ranks,
layers 2/3: p = 0.032, layer 4: p < 0.001, all post hoc com-
parisons vs. CFA by Dunn’s method). This effect was
normalized to CFA levels in the EAE-PLZ group (post
hoc comparison between EAE-PLZ and CFA not signifi-
cant, p > 0.05) (Fig. 4a–c).
We next examined spine densities in the same set of neu-
rons, grouping dendritic segments according to their rela-
tive position within their associated neuronal arbor. We
classified dendritic segments as either apical or basilar
branches and as primary, secondary, and tertiary branches.
We then analyzed all possible permutations of these cat-
egories (primary apical, primary basilar, secondary apical,
etc.). This “grouped” analysis allowed us to determine that
the increased spine density we observed at the neurites of
layer 2/3 neurons from the EAE-VEH group was almost
completely localized to the tertiary (i.e., the most distal den-
drites, in this classification) basilar branches. PLZ treatment
prevented or reversed these changes, as spine densities at
tertiary-basilar neurites were normalized to CFA levels
(Kruskal-Wallis one-way ANOVA on ranks, p = 0.007, all
post hoc comparisons vs. CFA by Dunn’s method) (Fig. 4b).
The distribution of layer 4 neuronal dendrites exhibiting el-
evated spine densities (i.e., from the EAE-VEH group) was
less specifically localized within the arbor. These increases
did not occur exclusively in either the apical or basilar tufts
or in the most proximal or distal dendrites. Rather, layer 4
neuronal dendrites from the EAE-VEH group exhibited a
significant increase in spine density specifically when con-
sidering second-order branches. Again, we found that PLZ
treatment normalized these densities to CFA levels (one-
way ANOVA, p < 0.001, all pairwise post hoc comparisons
by SNK method) (Fig. 4c).
Chronic PLZ treatment partially normalizes pre-synaptic
excitatory synaptic densities in S1 of mice with estab-
lished EAE
To investigate the long-term consequences of EAE on cor-
tical plasticity and how PLZ can affect these processes, we
assessed the effects of chronic PLZ treatment on cortical
pre-synaptic alterations in tissue taken at the fixed endpoint
of 21 dpi. This is a time past the “clinical-onset” phase,
when the disease has been fully established in the majority
of animals. At this later stage of the disease, perisomatic PV
staining within S1 was not significantly different between
CFA controls and VEH- or PLZ- treated EAE animals
(one-way ANOVA not significant, p = 0.661) (Fig. 5a, b). In
contrast, VGLUT1 staining in S1 remained significantly
denser in the VEH-treated EAE animals at 21 dpi compared
to CFA controls. This elevated VGLUT1 density was par-
tially diminished in the PLZ-treated EAE group, but not
completely normalized to CFA levels (one-way ANOVA,
layers 2/3: p = 0.014, layers 4/5: p = 0.007, all pairwise post
hoc comparisons by Holm-Sidak method) (Fig. 5c, d).
EAE is associated with a progressive loss of peri-neuronal
nets and microgliosis in S1
PV+ interneurons are often surrounded by organized com-
ponents of the extracellular matrix (ECMCs) known as
peri-neuronal nets (PNNs) [59]. Intact PNNs are essential
to maintaining the fast-inhibitory activity of PV+ interneu-
rons [60]. They are also known to be important regulators
of plasticity [61] and may be disrupted in disease states
[62]. We next assessed if PNNs were disrupted in the EAE
somatosensory cortex by staining with WFA lectin [63].
The number of intact PNNs was significantly diminished in
S1 of EAE animals beginning at clinical onset (one-way
ANOVA, p = 0.008, post hoc comparisons vs. CFA by Dun-
nett’s method) (see Additional file 2: Figure S1). This reduc-
tion in PNN numbers was persistent and was also observed
in S1 of EAE animals at the later 21 dpi time point. Chronic
PLZ treatment from 7 dpi did not restore or prevent the
decline of PNN numbers in EAE animals assessed at the
21 dpi time point (one-way ANOVA, p = 0.021, post hoc
comparisons vs. CFA by Dunnett’s method) (Fig. 6a, b).
We next sought to identify the potential disease-
related mechanism that leads to PNN loss and concur-
rent synaptic remodeling in EAE. As inflammation and
immune-mediated mechanisms have been implicated in
synaptic plasticity in EAE [20, 64, 65], and in the loss of
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PNNs in MS [66], we examined the state of neuroinflam-
mation in S1. We first performed immunostaining for
CD3 or CD45 expressing CNS-infiltrating leukocytes and
T cells. CD3+ T cells and CD45+ leukocytes were not
present in S1 at either the pre-symptomatic or clinical-






































































Fig. 4 Morphological changes in spiny excitatory neurons of S1 in EAE, and PLZ-treated EAE, at clinical onset. a Representative maximum z-projected
images showing appearance and density of spines on dendritic segments from spiny excitatory neurons in S1. Spines were visualized by reflectance-
mode (488 nm) laser-scanning confocal microscopy on Golgi-Cox stained brains from VEH-treated CFA (CFA), VEH-treated EAE (VEH), and PLZ-treated
EAE (PLZ) animals at clinical onset. b Mean (±S.E.) dendritic-spine densities assessed from the branches of spiny neurons in layers 2/3 of S1 from CFA-
VEH (n = 42 dendritic segments, 4 animals), EAE-VEH (n = 66 dendritic segments, 8 animals), and EAE-PLZ mice (n = 78 dendritic segments, 9 animals).
Dendritic segments from EAE-VEH animals exhibited significantly increased spine-densities compared to segments from CFA-VEH mice. This increase
was localized almost exclusively to the tertiary basilar branches (CFA-VEH n = 12, EAE-VEH n = 13, EAE-PLZ n = 14 dendritic segments). Daily treatment
with PLZ from 7 dpi prevented or reversed this increase—mean spine-densities along segments from EAE-PLZ animals did not significantly differ from
CFA controls (Kruskal-Wallis one-way ANOVA on ranks; “all-branches” p = 0.032; tertiary-basilar branches p = 0.007, all post hoc comparisons vs.
CFA controls by Dunn’s method). c Mean (±S.E.) dendritic-spine densities assessed from the branches of spiny neurons in layer 4 of S1
from CFA-VEH (n = 36 dendritic segments, 4 animals), EAE-VEH (n = 58 dendritic segments, 8 animals), and EAE-PLZ mice (n = 83 dendritic
segments, 10 animals). Dendritic segments from EAE-VEH animals exhibited significantly increased spine-densities compared to segments
from CFA-VEH mice. This increase was also specifically significant for second-order branches (CFA-VEH n = 23, EAE-VEH n = 43, EAE-PLZ n = 54 dendritic
segments). Daily treatment with PLZ prevented or reversed this increase—mean spine densities along segments from EAE-PLZ animals did not
significantly differ from CFA-controls but were significantly reduced vs. the EAE-VEH group (“all-branches” analyzed by Kruskal-Wallis one-way ANOVA
on ranks, p < 0.001; post hoc comparisons vs. CFA controls by Dunn’s method. Secondary branches analyzed by one-way ANOVA, p < 0.001, all pairwise
post hoc comparisons by SNK test)
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did, however, observe significantly increased numbers of
Iba-1+ microglia at both of these early disease time points
(one-way ANOVA, p = 0.012, all post hoc comparisons vs.
CFA by Dunnett’s method). This increase in cortical Iba-1
+ microglia was also observed in tissues from late-stage
EAE animals that were treated with VEH at 21 dpi. Not-
ably, chronic PLZ treatment normalized Iba-1+ cell
counts in S1 of EAE animals at 21 dpi (one-way ANOVA,
p = 0.009, all post hoc comparisons vs. CFA by Dunnett’s
method) (Fig. 6c, d).
Discussion
This study is the first investigation of functional neocor-




























































































Fig. 5 Perisomatic PV+ and VGLUT1+ reactivity and the effects of PLZ treatment in established EAE. a–c Representative confocal z-projections of
PV+ somas and terminals (green) in layers 2/3 of S1, in control (CFA), VEH-treated EAE (21 dpi, VEH), and PLZ-treated EAE (21 dpi, PLZ) animals
(treated from 7 dpi). White arrowheads indicate PV+ somas; magenta arrowheads indicate putative pyramidal-neuron “shadows” targeted for quantification.
d Group mean (±S.E.) normalized density values corresponding to perisomatic PV+ staining surrounding layer 2/3 neurons in S1. Control (CFA) (n= 8),
VEH-treated EAE (n= 4), and PLZ-treated EAE (n = 4) animals did not differ from each another at this time point (one-way ANOVA not significant,
p = 0.661). e–g Representative fluorescence photomicrographs of VGLUT1+ staining (red) in layers 2/3 of S1; in control (CFA), VEH-treated EAE
(21 dpi, VEH), and PLZ-treated EAE (21 dpi, PLZ) animals (treated from 7 dpi). DAPI (cell-nuclei) counter-stain is shown in blue. h Group mean
(±S.E.) integrated densities of VGLUT1+ stained CFA (n = 5), EAE-VEH (n = 5), and EAE-PLZ (n = 4) animals. VEH-treated EAE animals retained
strongly increased VGLUT1+ density in layer 2/3 S1 vs. CFA controls. PLZ treatment from 7 dpi significantly reduced VGLUT1+ density in EAE
animals but did not normalize to CFA-levels (one-way ANOVA, p = 0.014, all pairwise post hoc comparisons performed by Holm-Sidak method).
i–k Representative fluorescence photomicrographs of VGLUT1+ staining (red) in layers 4/5 of S1; in control (CFA), VEH-treated EAE (21 dpi, VEH), and
PLZ-treated EAE (21 dpi, PLZ) animals (treated from 7 dpi.). DAPI (cell-nuclei) counter-stain is shown in blue. l Group mean (±S.E.) integrated densities of
VGLUT1+ stained CFA (n = 5), EAE-VEH (n = 5), and EAE-PLZ (n = 4) animals. VEH-treated EAE animals retained strongly increased VGLUT1+ density in
layers 4/5 of S1 vs. CFA controls. PLZ treatment from 7 dpi significantly reduced VGLUT1+ density in EAE animals but did not normalize to CFA-levels
(one-way ANOVA, p = 0.007, all pairwise post hoc comparisons performed by Holm-Sidak method)
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and synaptic changes occurring in S1 in the very early
stages of the C57/BL6 MOG35–55 EAE model. Specific-
ally, we find in vivo evidence in early EAE of enhanced
intensity and spread of the neuronal activation within S1
that is evoked by vibrotactile stimulation of the fore- or
hindlimb. Interestingly, a delay exists between the “pre-
symptomatic” and “clinical-onset” time points in the
sensitization of responses to forelimb stimulation. This
delay mirrors the caudal-to-rostral progression of spinal
inflammation and paralysis in EAE [67] and suggests
that ascending sensitization within the SC-DH [12] may
precede (or initiate) sensitization of supraspinal sites, as
has been observed in other models of neuropathic pain
and allodynia [8, 23, 24].
In addition to the observed enhancement of functional
responses, we find histological evidence of an increased
density of excitatory pre-synaptic (VGLUT1+) terminals
and post-synaptic contacts (dendritic spines) in cortical
layers 2/3 and 4/5 of S1 in early EAE. These changes are
indicative of pro-excitatory remodeling of the major
feed-forward circuit through S1 [47], in which layer 4
principal neurons receive thalamocortical inputs [68]
and project vertically to pyramidal neurons of layer 2/
3—primarily to the distal/basilar branches. Abundant
transcolumnar connections in layer 2/3 mediate the
horizontal spread of activation through S1, defining the
areal extent of a “functional map” [53, 69]. Synaptic re-
modeling along this pathway therefore likely contributes
to the intensification and expansion of S1 functional re-
sponses in early EAE [70]. These alterations occur prior
to the onset of major paresis and temporally coincide
with the appearance of prominent pain behaviors in the
disease. Moreover, similar functional and synaptic alter-
ations occurring in S1 have been shown to play a causal
role in other neuropathic pain models [7, 8].
We also find evidence in EAE of an early, although
transient, disruption of target-cell innervation by basket-













































Fig. 6 Microglial activation and peri-neuronal net integrity in S1, and the effects of PLZ, in established EAE. a Representative fluorescence
photomicrographs of WFA+ staining (PNNs) in S1 from control (CFA) animals and EAE animals treated from 7 dpi with either (VEH) or
(PLZ). A’ (inset) High-magnification confocal photomicrograph depicting PNNs (WFA+, magenta) surrounding PV+ interneurons (green) in
S1HL. DAPI (cell-nuclei) counter-stain is shown in blue. b Group mean (±S.E.) total PNN counts from WFA+ stained S1HL of CFA (n = 6),
VEH-treated EAE (n = 7), and PLZ-treated (n = 4) EAE animals (21 dpi). VEH-treated EAE animals exhibited significantly reduced PNN-counts
in S1HL vs. CFA controls. PNN counts from the PLZ-treated EAE mice were also significantly reduced compared to CFA. PNN counts were
approximately equivalent (not significant, p > 0.05) between both the VEH-treated and PLZ-treated EAE groups (one-way ANOVA, p = 0.021,
post hoc comparisons vs. CFA controls by Dunnett’s method). c Representative fluorescence photomicrographs of Iba-1+ staining (activated microglia/
macrophages) in S1HL of CFA animals and EAE animals treated chronically from 7 dpi with either (VEH) or (PLZ). d Group mean (±S.E.) counts of Iba-1+
cells in S1HL of CFA (n= 6), VEH-treated EAE (n= 7), or PLZ-treated EAE (n= 4) animals. VEH-treated EAE animals exhibited significantly increased numbers
of Iba-1+ cells in S1HL vs. CFA controls. Chronic treatment of EAE mice with PLZ from 7 dpi reduced the number of Iba-1+ cells in S1HL—EAE-PLZ animals
did not differ significantly from CFA controls (one-way ANOVA, p= 0.009, post hoc comparisons vs. CFA controls by Dunnett’s method)
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role of PV-mediated fast-spiking inhibition in limiting
the extent to which large-scale plastic changes may
occur in the neocortex, during both adulthood and the
perinatal critical period, is well documented in the litera-
ture [71, 72]. Even a transient loss of PV-mediated peri-
somatic inhibition in early EAE might therefore have
profound and lasting consequences, leading to a dysreg-
ulated E-I balance and maladaptive cortical plasticity
[73]. Moreover, we find that PV+ interneurons are af-
fected in EAE by an early-appearing and persistent loss
of their associated PNN structures. PNNs serve multiple
supportive and protective functions for PV+ neurons, in-
cluding sequestering cations (i.e., Ca2+) to support fast-
spiking activity, limiting synaptic modifications and
alterations of connectivity, and protecting the neurons
against chemical insults such as reactive oxygen species
(ROS) [59]. The loss of PNNs may therefore be a key
precipitating factor in the aberrant structural and synap-
tic plasticity we find in both the inhibitory and excitatory
circuitry of S1 in early EAE. Loss of PNNs may addition-
ally contribute to the unique susceptibility of PV+ inter-
neurons to degeneration in the later stages of EAE/MS,
which has been reported by several groups [21, 74, 75].
Collectively with our previous findings [12, 28], the
multiple functional and synaptic changes in S1 evi-
denced in this study provide support for the hypothesis
that EAE involves a profound, pro-excitatory, shift in the
E-I balance of the entire somatosensory CNS, beginning
very early in the disease course. This disrupted E-I bal-
ance promotes functional and structural plasticity within
S1 [30, 71], leading to amplified cortical responses to
peripheral stimuli and likely contributing to pain behav-
iors (i.e., allodynia) in the disease [7, 23, 31].
While we are the first group to find an increase in
both pre- and post-synaptic glutamatergic markers and a
concurrent reduction in perisomatic PV+ immunoreac-
tivity in S1 in early EAE, several other groups have found
similar or complementary changes in the EAE/MS brain
[21, 74, 75]. A report by Yang et al. (2014) demonstrated
enhanced turnover of dendritic spines and axonal boutons
in layer 5 pyramidal neurons within S1 in early MOG35–55
EAE [19]. As mentioned, loss of PV+ interneurons in EAE
has also been demonstrated by several groups in multiple
brain regions, including primary motor cortex [21, 64, 76].
A single report by Tambolo et al. (2015) also suggested,
based on functional magnetic resonance imaging (fMRI)-
blood-oxygen-level-dependent (BOLD) data, that the later
stages (30–60 dpi) of the Lewis rat model of EAE involve
functional expansion of the vibromechanically evoked S1
forelimb representation [20]. This study also found den-
dritic spine loss in layer 2/3 and 4 neurons of S1. While
some of the findings and interpretations offered in Tambolo
et al. (2015) appear to contrast with our observations, it is
worth noting that there are significant methodological
differences between the studies. Furthermore, inferences
about neural activation based strictly on the fMRI-BOLD
signal may potentially be confounded by hemodynamic
changes in the disease state. Nevertheless, much agreement
exists between these various reports. Indeed, a substantial
body of evidence is emerging that early synaptopathy in
EAE and MS brains leads progressively to neuronal hyper-
excitability, plasticity, excitotoxicity, and eventual dysfunc-
tion and degeneration [21, 65, 77]. In the majority of these
studies, inflammation and circulating pro-inflammatory
cytokines have been proposed as the proximal causative
factors [10, 11].
In our examination of the role that inflammation plays in
initiating or promoting cortical alterations in EAE, we first
examined tissues for infiltrating CD3+ T cells and CD45+
leukocytes. As noted, brain-penetrating T cells were absent
from S1 at these early stages in our model. However, intra-
cortical Iba-1-reactive microglia were found to be signifi-
cantly more abundant in EAE compared to CFA controls,
both pre-symptomatically (7 dpi), and in the established
disease (21 dpi). Previous groups have suggested multiple
contributing roles for reactive microglia in EAE/MS-related
synaptopathies [10, 11]. Microglia are capable of modifying
neuronal connectivity through multiple mechanisms, in-
cluding the secretion of diffusible factors such as matrix
metalloproteases (i.e., matrix metalloproteinase (MMP)-2,
MMP-9), which digest ECMCs such as PNNs, and are
known to be elevated in the brain in EAE/MS [78]. React-
ive microglia also secrete cytokines, such as soluble tumor
necrosis factor (sTNF)-α and interleukin (IL)-1β [79, 80]
which have been shown to promote synaptic plasticity and
scaling, and neuronal hyperexcitability in EAE [19]. Micro-
glia are furthermore responsive to many activity-dependent
signals, such as extracellular glutamate and adenosine tri-
phosphate (ATP) [81]. The pro-excitatory state found in
early EAE cortex therefore likely acts to promote microglial
reactivity in a feed-forward manner.
In addition to characterizing cortical functional and syn-
aptic changes in early EAE, we also demonstrated a novel
antinociceptive effect of PLZ treatment in the disease.
Chronic treatment with PLZ from 7 dpi, when early cortical
and behavioral alterations are already established, fully nor-
malized mechanical withdrawal thresholds in EAE mice at
clinical onset. Significantly, we also demonstrated that PLZ
treatment normalizes S1 functional responses in EAE at on-
set. Furthermore, PLZ treatment attenuated S1 structural
and synaptic abnormalities–normalizing dendritic spine
densities at clinical onset and attenuating VGLUT1 reactiv-
ity in the established disease (21 dpi). Notably, this result
highlights the possibility that, given the proper intervention,
disease-related synaptopathies may be reversible. PLZ re-
stores CNS levels of GABA in EAE through the inhibition
of GABA-T by its active metabolite phenylethylidenehydra-
zine (PEH) and restores monoamine levels by the
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irreversible inhibition of MAO-A and B [29]. PLZ has previ-
ously been shown to enhance functional intracortical GABA
release [82–84]. The enhancement of the GABA-AR-
mediated [55, 56] surround-inhibitory FAI signal we find in
PLZ-treated EAE mice supports this proposed mechanism
of action. Other groups have also suggested that PLZ may
attenuate excessive cortical glutamate release by affect-
ing glutamate-glutamine (neuron-astrocyte) shuttling and
conversion [85, 86]. Defective astrocytic reuptake and me-
tabolism has been suggested to promote excessive synaptic
glutamate and CNS hyperexcitability in EAE/MS [10–12].
While PLZ treatment in EAE did not rescue disrupted
PNNs, it significantly reduced Iba-1+ cells within S1. Just
as excitatory signaling can promote microglial reactivity,
inhibitory signaling through G protein-coupled receptors,
such as GABA-BRs [87] and adrenergic receptors [88], can
reduce microglial motility and reactivity. Enhancement of
GABAergic/monoaminergic neurotransmission and the
concomitant reduction of excitatory signaling may there-
fore be the means by which PLZ treatment reduces cor-
tical microgliosis in EAE. This synergistic neuroglial action
likely aids in the restoration of normal constraints on plas-
ticity within the somatosensory CNS and contributes to
the normalization of pain behaviors in EAE. PLZ treat-
ment does not induce a generalized analgesic or sedative
effect, as it produced no significant changes in basal mech-
anical sensitivity or motor function in control (CFA) ani-
mals. PLZ also did not affect evoked S1 functional
responses in control (CFA) animals.
Although the current experiments did not involve direct
manipulation of the sensory cortex in a way that might
conclusively establish an immediate causal link between
altered S1 structure/function and altered pain behaviors in
EAE, the complete dissociation of responses to PLZ treat-
ment in non-disease controls and EAE animals supports
the hypothesis that maladaptive cortical plasticity and hy-
perexcitability within S1 directly contributes to pain in the
disease.
Conclusions
The evidence presented here supports a link between al-
tered central E-I balance, maladaptive functional and struc-
tural plasticity in S1, and increased pain behaviors in early
EAE. The PLZ experiments demonstrate, in principle, that
a treatment which acts to restore lost CNS inhibitory func-
tion can normalize pain behaviors and S1 synaptic structure
and function in EAE. By focusing our investigation on the
early stages of EAE—when pain is first becoming estab-
lished and when initiating pathogenic and synaptic changes
occur—we hope to highlight the possibility that early thera-
peutic intervention, perhaps with a “combined-action”
agent similar to PLZ, may be invaluable for preventing the
development of CNP states in MS patients. For those pa-
tients with established CNP, and other “secondary”
symptoms of MS, the potentially reversible nature of CNS
synaptopathy—as demonstrated here—also provides hope
that certain aspects of the disease might also be effectively
reverted through targeted interventions.
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Additional file 1: Video 1. In vivo FA imaging of vibrotactile-evoked
responses in S1 at the pre-symptomatic stage of EAE. Representative
hindlimb-evoked FAI responses in S1 for naïve, CFA, and EAE animals at
the pre-symptomatic time point. (MOV 10708 kb)
Additional file 2: Figure S1. S1 IHC in pre-symptomatic and clinical-onset
EAE: PV+ cell counts, PNN counts, and Iba-1+ microglia counts. A)
Representative fluorescence photomicrographs of PV+ staining (low-mag) in
S1 from control (CFA) and EAE animals at the pre-symptomatic stage (7–9 dpi
PRE) or clinical onset (ONS). B) Group mean (±S.E.) total PV+ cell counts from
S1HL of CFA (n= 8), PRE (n= 4), and ONS (n= 4) EAE animals. No significant
differences were observed between groups (one-way ANOVA N.S.). C)
Representative fluorescence photomicrographs of WFA+ staining (PNNs) in S1
from control (CFA) and EAE animals at the pre-symptomatic stage (7–9 dpi
PRE) or clinical onset (ONS). D) Group mean (±S.E.) total PNN counts from
S1HL of CFA (n = 11), PRE (n = 4), and ONS (n = 8) EAE animals. EAE
animals exhibited significantly reduced PNN-counts vs. CFA-controls
at clinical onset (one-way ANOVA, p = 0.007, post hoc comparisons
vs. CFA-controls by Dunnett’s method). E) Representative fluorescence
photomicrographs of Iba-1+ staining (PNNs) in S1 from control (CFA)
and EAE animals at the pre-symptomatic stage (7–9 dpi PRE) or clinical onset
(ONS). F) Group mean (±S.E.) total Iba-1+ counts from S1HL of CFA (n= 13),
PRE (n = 4), and ONS (n = 8) EAE animals. EAE animals exhibited
significantly increased numbers of Iba-1+ cells (microglial activation)
in S1HL vs. CFA-controls at all time points (one-way ANOVA, p = 0.012, post
hoc comparisons vs. CFA-controls by Dunnett’s method). (PDF 6418 kb)
Additional file 3: Figure S2. PLZ-treatment delays the onset of clinical
symptoms of EAE. Mean number of days (post-induction) to clinical onset
(grade >0) in animals treated with vehicle (VEH, n = 26) or phenelzine
(PLZ, n = 27) since 7 dpi. PLZ delayed the clinical onset of EAE by several
days (t test, p = 0.041). (PDF 76 kb)
Additional file 4: Video 2. In vivo FAI of vibrotactile-evoked responses
in S1 of EAE and PLZ-treated EAE animals at clinical onset. Representative
hindlimb-evoked FA responses in S1 for vehicle-treated CFA (CFA-VEH),
phenelzine-treated CFA (CFA-PLZ), vehicle-treated EAE (EAE-VEH), and
phenelzine-treated EAE (EAE-PLZ) animals at clinical onset. (MOV 19447 kb)
Additional file 5: Figure S3. In vivo FAI of forelimb vibrotactile-evoked
responses in S1 of EAE and PLZ-treated EAE animals at clinical onset. A)
Balanced-contrast pseudocolored montages of representative S1 hindlimb
responses from VEH/PLZ-treated CFA/EAE animals at clinical onset. B) Group
mean (±S.E.) forelimb intensities at peak FA response, calculated from the
“cortical map” area as a percent change in fluorescence vs. baseline (%ΔF/F).
VEH-treated EAE animals at clinical onset (n = 7) exhibited significantly
intensified responses to vibrotactile stimulation of the forelimb, compared to
CFA controls (n = 8). PLZ-treated EAE (n = 9) and PLZ-treated CFA (n = 4)
animals did not significantly differ from CFA (Kruskall-Wallis one-way
ANOVA on ranks, p< 0.001; all post hoc comparisons vs. CFA-VEH controls by
Dunn’s method). C) Group mean (±S.E.) forelimb FA response areas. EAE-VEH
animals at onset (n= 7) exhibited significant expansion of hindlimb responses
compared to CFA-VEH controls (n= 8), CFA-PLZ (n= 4), and EAE-PLZ animals
(n= 9). CFA-VEH, CFA-PLZ, and EAE-PLZ groups did not significantly differ
(Kruskall-Wallis one-way ANOVA on ranks not significant, p = 0.912).
(PDF 545 kb)
Additional file 6: Figure S4. S1 IHC in pre-symptomatic and clinical onset
EAE: absence of cortical-infiltrating CD3+ and/or CD45+ T cells. A)
Representative fluorescence photomicrographs of CD3+ staining in
S1 from control (CFA) and EAE animals at the pre-symptomatic stage
(7–9 dpi PRE) or clinical onset (ONS). No infiltrating T cells were apparent. B)
Representative fluorescence photomicrographs of CD45+ staining in S1 from
control (CFA) and EAE animals at the pre-symptomatic stage (7–9 dpi PRE)
or clinical onset (ONS). No infiltrating T cells were apparent. (PDF 1663 kb)
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